Immuno MABs 3

Card Set Information

Author:
kyleannkelsey
ID:
291664
Filename:
Immuno MABs 3
Updated:
2014-12-15 13:35:34
Tags:
Immuno MABs
Folders:
Immuno MABs 3
Description:
Immuno MABs 3
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user kyleannkelsey on FreezingBlue Flashcards. What would you like to do?


  1. TOSITUMOMAB
    (Bexxar)
  2. (Bexxar)
    TOSITUMOMAB
  3. TOSITUMOMAB (Bexxar)
    • CD20 receptors.
    • conjugated to Iodine-131.
    • non-Hodgkin’s lymphoma, all expressing CD20 antigen.
    • The administration is done in two steps 7-14 days apart and each step has two components
  4. (Adcatris)
    Brentuximab vedotin
  5. Brentuximab vedotin
    (Adcatris)
  6. Brentuximab vedotin (Adcatris)
    • CD30
    • classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    • attached to an antimitotic agent monomethyl auristatin E.
    • internalized by endocytosis and selectively targets the tumor cells.
    • Chemotherapy-induced peripheral neuropathy
  7. PANITUMUMAB
    (Vectibix)
  8. (Vectibix)
    PANITUMUMAB
  9. (Vectibix)
    PANITUMUMAB
  10. PANITUMUMAB
    (Vectibix)
  11. PANITUMUMAB (Vectibix)
    • (IgG2)
    • epidermal growth factor receptors EGFR
    • colorectal cancer in patients who have not responded well to standard
    • EGFR which plays a role in resistance to chemotherapy and radiation.
  12. (Erbitux)
    CENTUXIMAB
  13. CENTUXIMAB
    (Erbitux)
  14. CENTUXIMAB (Erbitux)
    • (IgG1)
    • epidermal growth factor receptors (HER1)
    • expressed on epithelial tissue as well as on the tumors of the colon, rectum, head and neck.
    • suppresses cell growth and decreases in the production of matrix metalloproteinase and vascular endothelial growth factor.
    • head, neck and colorectal cancers and in combination with radiation therapy it is indicated for the treatment of squamous cell carcinoma
    • not given in combination with radiation to patients who did not exhibit a good response to platinum-based therapy.
  15. (Avastin)
    BEVACIZUMAB
  16. BEVACIZUMAB
    (Avastin)
  17. BEVACIZUMAB (Avastin)
    • (IgG1)
    • vascular endothelial growth factor (VEGF)
    • VEFG promotes the proliferation of endothelial cells and formation of new blood vessels.
    • In combination with a standard chemotherapeutic regimen (5-fuouracil-based) it is used for the treatment of patients with malignant colon or rectal cancer.
  18. (Yervoy)
    IPILIMUMAB
  19. IPILIMUMAB
    (Yervoy)
  20. IPILIMUMAB (Yervoy)
    • malignant melanoma.
    • It binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4).
    • CTLA-4 is expressed on the surface of helper and regulatory T cells.
    • CTLA-4 binds to CD80 and CD86 (B7) on antigen presenting cells.
    • CTLA-4 regulates T cell responses in fighting disease.
    • The antibody blocks the function of CTLA-4, resulting in a sustained immune response that attacks the cancer cells.
    • The drug causes an increase in the percentage of activated HLA-DR+ T cells and a mean decrease in the percentage of CCR7+ CD45RA+ T cells.

What would you like to do?

Home > Flashcards > Print Preview